Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 6Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Sarcoma 1Radiation Pneumonitis 1Pancreatic Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Inflammatory Breast Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Breast Neoplasms 1Appendiceal Neoplasms 1

Interventions

Carboplatin 44Paclitaxel 43liposomal doxorubicin 23Topotecan 19Gemcitabine 18pembrolizumab 17Cyclophosphamide 17Bevacizumab 16Cisplatin 12niraparib 9olaparib 8fludarabine 7Taxes 7Docetaxel 7aldesleukin 6Nivolumab 6Doxorubicin 61-dodecylpyridoxal 6oregovomab 5fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5rucaparib 4durvalumab 4avelumab 4Surgical Procedures, Operative 4Melphalan 4Ipilimumab 4Interleukin-2 4Etoposide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Ovarian Neoplasms × nintedanib × Clear all
NCT01485874 2022-02-15

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

Hoosier Cancer Research Network

Phase 1 Terminated
11 enrolled
Gynecologic

Ovarian Neoplasms

NCT01329549 2014-11-27

Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

Boehringer Ingelheim

Phase 1 Terminated
2 enrolled 5 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡